{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:02:52Z","timestamp":1765609372555,"version":"3.35.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.3816\/clm.2002.n.016","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:09:54Z","timestamp":1221095394000},"page":"105-110","source":"Crossref","is-referenced-by-count":52,"title":["Cytomegalovirus Viremia During Campath-1H Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia"],"prefix":"10.3816","volume":"3","author":[{"given":"Dorothy D.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thai M.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey A.","family":"Starcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Lenn","family":"Fechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2002.n.016_bib1","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath- 1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.016_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.016_bib3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2002.n.016_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1634\/stemcells.20-3-215","article-title":"Cell surface antigen and molecular targeting in the treatment of hematologic malignancies","volume":"20","author":"Countouriotis","year":"2002","journal-title":"Stem Cells"},{"key":"10.3816\/CLM.2002.n.016_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00001622-200011000-00010","article-title":"Campath-1H monoclonal antibody therapy","volume":"12","author":"Flynn","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2002.n.016_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","article-title":"Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia","volume":"93","author":"Osterborg","year":"1996","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.016_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00277-001-0394-7","article-title":"Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non- Hodgkin's lymphomas: a multicenter phase I\/II study","volume":"81","author":"Uppenkamp","year":"2002","journal-title":"Ann Hematol"},{"key":"10.3816\/CLM.2002.n.016_bib8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-2141.2001.03039.x","article-title":"The effect of treatment with Campath- 1H in patients with autoimmune cytopenias","volume":"114","author":"Willis","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2002.n.016_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","article-title":"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement","volume":"62","author":"Hale","year":"1983","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.016_bib10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia","volume":"44","author":"Issacs","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.3816\/CLM.2002.n.016_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/10428199609045717","article-title":"Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma","volume":"24","author":"Tang","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2002.n.016_bib12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood.V99.6.2245","article-title":"Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia","volume":"99","author":"Kennedy","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.016_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.016_bib14","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.016_bib15","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2002.n.016_bib16","series-title":"Hematopoeitic Cell Transplantation","first-page":"560","article-title":"Cytomegalovirus Infections","author":"Zaia","year":"1999"},{"key":"10.3816\/CLM.2002.n.016_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.3816\/CLM.2002.n.016_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CLM.2002.n.016_bib19","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.3816\/CLM.2002.n.016_bib20","series-title":"Chronic lymphocytic leukemia. Recent progress and future directions","first-page":"253","article-title":"A critical analysis of staging in CLL","author":"Rai","year":"1987"},{"key":"10.3816\/CLM.2002.n.016_bib21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/JCM.38.6.2122-2127.2000","article-title":"Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients","volume":"38","author":"Caliendo","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.3816\/CLM.2002.n.016_bib22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/00007890-199911150-00015","article-title":"Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients","volume":"68","author":"Humar","year":"1999","journal-title":"Transplantation"},{"key":"10.3816\/CLM.2002.n.016_bib23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/JCM.38.2.600-606.2000","article-title":"Evaluation of the COBAS Amplicor CMV monitor test for detection of viral DNA in specimens taken from patients after liver transplantation","volume":"38","author":"Sia","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.3816\/CLM.2002.n.016_bib24","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/JCM.40.5.1581-1586.2002","article-title":"Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays","volume":"40","author":"Caliendo","year":"2002","journal-title":"Journal of Clinical Microbiology"},{"key":"10.3816\/CLM.2002.n.016_bib25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1128\/JCM.38.2.600-606.2000","article-title":"Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation","volume":"38","author":"Sia","year":"2000","journal-title":"Journal of Clinical Microbiology"},{"key":"10.3816\/CLM.2002.n.016_bib26","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1128\/JCM.39.11.3938-3941.2001","article-title":"Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation","volume":"39","author":"Solano","year":"2001","journal-title":"Journal of Clinical Microbiology"},{"key":"10.3816\/CLM.2002.n.016_bib27","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/JCM.36.9.2509-2513.1998","article-title":"Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virusinfected subjects","volume":"36","author":"Boivin","year":"1998","journal-title":"Journal of Clinical Microbiology"},{"key":"10.3816\/CLM.2002.n.016_bib28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1070884","article-title":"Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors","volume":"296","author":"Arase","year":"2002","journal-title":"Science"},{"key":"10.3816\/CLM.2002.n.016_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2567.1996.d01-650.x","article-title":"Repopulation of blood lymphocyte subpopulations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H","volume":"88","author":"Brett","year":"1996","journal-title":"Immunology"},{"key":"10.3816\/CLM.2002.n.016_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00001622-200001000-00004","article-title":"Update on the biology of chronic lymphocytic leukemia","volume":"12","author":"Bannerji","year":"2000","journal-title":"Current Opinion in Oncology"},{"key":"10.3816\/CLM.2002.n.016_bib31","first-page":"27","article-title":"Impairments in immune cell function in B cell chronic lymphocytic leukemia","volume":"25","author":"Bartik","year":"1998","journal-title":"Seminars in Oncology"},{"key":"10.3816\/CLM.2002.n.016_bib32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nm0997-984","article-title":"Acquired CD40-ligand deficiency in chronic lymphocytic leukemia","volume":"3","author":"Cantwell","year":"1997","journal-title":"Nature Medicine"},{"key":"10.3816\/CLM.2002.n.016_bib33","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","article-title":"Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population","volume":"94","author":"Perkins","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2002.n.016_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00001432-200108000-00002","article-title":"Infectious complications of purine analog therapy","volume":"14","author":"Samonis","year":"2001","journal-title":"Current Opinion in Infectious Diseases"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T22:10:45Z","timestamp":1738361445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511702573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1526965511702573"],"URL":"https:\/\/doi.org\/10.3816\/clm.2002.n.016","relation":{},"ISSN":["1526-9655"],"issn-type":[{"type":"print","value":"1526-9655"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}